(Q38099727)

28 August 2017

title

Mechanisms of action of anti-tumor necrosis factor α agents in Crohn's disease (English)

1 reference

28 August 2017

0 references

David Bernardo

2

0 references

Elizabeth R Mann

series ordinal

3

object named as

Elizabeth R Mann

1 reference

28 August 2017

5

Stella C Knight

1 reference

28 August 2017

6

Ailsa L Hart

1 reference

28 August 2017

Simon T C Peake

1

1 reference

28 August 2017

Hafid O Al-Hassi

series ordinal

4

1 reference

28 August 2017

publication date

1 June 2013

1 reference

Inflammatory Bowel Diseases

28 August 2017

published in

1 reference

28 August 2017

volume

19

1 reference

28 August 2017

issue

7

1 reference

28 August 2017

page(s)

1546-1555

1 reference

An endotoxin-induced serum factor that causes necrosis of tumors

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

TNF pathophysiology in murine models of chronic inflammation and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

The pathophysiology of tumor necrosis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

The tumor necrosis factor ligand and receptor families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Two tumour necrosis factor receptors: structure and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Tumor necrosis factor receptor and Fas signaling mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Reverse signaling through transmembrane TNF confers resistance to lipopolysaccharide in human monocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Certolizumab pegol for the treatment of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Infliximab maintenance therapy for fistulizing Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Dynamics of enterocyte tight junctions: effect of experimental colitis and two different anti-TNF strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

How T lymphocytes switch between life and death

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

The proto-oncogene Bcl-2 and its role in regulating apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

The Bcl-2 protein family: arbiters of cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Angiogenesis and vasculogenesis in rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Angiogenesis as a novel component of inflammatory bowel disease pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Role of cytokines in the pathogenesis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Dendritic cells and the control of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Mode of function of biological anti-TNF agents in the treatment of inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

The CD40/CD40L costimulatory pathway in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Regulatory macrophages induced by infliximab are involved in healing in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Cross-regulation of TNF and IFN-alpha in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

Predictive Factors of Eczema-Like Eruptions among Patients without Cutaneous Psoriasis Receiving Infliximab: A Cohort Study of 92 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2FMIB.0B013E318281333B

10.1097/MIB.0B013E318281333B

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference